338.91
前日終値:
$312.11
開ける:
$350
24時間の取引高:
1.23M
Relative Volume:
3.47
時価総額:
$7.52B
収益:
-
当期純損益:
$-518.67M
株価収益率:
-13.49
EPS:
-25.12
ネットキャッシュフロー:
$-438.32M
1週間 パフォーマンス:
+15.12%
1か月 パフォーマンス:
+13.40%
6か月 パフォーマンス:
-0.31%
1年 パフォーマンス:
+30.63%
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
名前
Madrigal Pharmaceuticals Inc
セクター
電話
404-380-9263
住所
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MDGL
Madrigal Pharmaceuticals Inc
|
338.91 | 6.93B | 0 | -518.67M | -438.32M | -25.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-28 | アップグレード | B. Riley Securities | Neutral → Buy |
2025-02-27 | 繰り返されました | H.C. Wainwright | Buy |
2024-06-28 | 開始されました | Cantor Fitzgerald | Neutral |
2024-06-11 | 開始されました | Wolfe Research | Outperform |
2024-04-22 | 開始されました | BofA Securities | Underperform |
2024-03-15 | アップグレード | B. Riley Securities | Sell → Neutral |
2024-03-06 | 開始されました | Citigroup | Buy |
2024-02-26 | ダウングレード | B. Riley Securities | Neutral → Sell |
2022-12-20 | 繰り返されました | Oppenheimer | Outperform |
2022-12-19 | 繰り返されました | H.C. Wainwright | Buy |
2022-12-19 | 繰り返されました | Piper Sandler | Overweight |
2022-12-19 | アップグレード | Raymond James | Underperform → Mkt Perform |
2022-07-08 | ダウングレード | B. Riley Securities | Buy → Neutral |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-08-06 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2021-05-20 | 再開されました | Goldman | Buy |
2020-11-24 | 再開されました | Evercore ISI | Outperform |
2020-11-06 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-31 | 開始されました | Piper Sandler | Overweight |
2020-06-05 | 開始されました | BMO Capital Markets | Market Perform |
2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
2020-01-30 | 開始されました | Canaccord Genuity | Buy |
2020-01-09 | アップグレード | UBS | Neutral → Buy |
2019-11-07 | 繰り返されました | H.C. Wainwright | Buy |
2019-06-25 | 開始されました | Stifel | Hold |
2019-06-10 | アップグレード | B. Riley FBR | Neutral → Buy |
2019-02-28 | 繰り返されました | H.C. Wainwright | Buy |
2019-02-22 | 開始されました | SVB Leerink | Outperform |
2019-01-23 | 開始されました | UBS | Neutral |
2018-12-14 | 開始されました | Wolfe Research | Outperform |
2018-12-12 | 開始されました | B. Riley FBR | Neutral |
2018-11-19 | ダウングレード | Raymond James | Mkt Perform → Underperform |
2018-11-16 | アップグレード | Evercore ISI | In-line → Outperform |
2018-09-04 | 開始されました | Citigroup | Buy |
2018-08-06 | ダウングレード | Goldman | Buy → Neutral |
2018-06-28 | 開始されました | Raymond James | Mkt Perform |
すべてを表示
Madrigal Pharmaceuticals Inc (MDGL) 最新ニュース
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox
Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
China momentum continues with Madrigal-CSPC, Arrowhead- Sanofi tie-ups: Deals Report - BioCentury
How strong is Madrigal Pharmaceuticals Inc. company’s balance sheetOutstanding capital growth - Jammu Links News
Is Madrigal Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with advanced market data - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockHigh-profit trading signals - Jammu Links News
How does Madrigal Pharmaceuticals Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
How volatile is Madrigal Pharmaceuticals Inc. stock compared to the marketBuild wealth with reliable stock picks - Jammu Links News
West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light - MSN
What are Madrigal Pharmaceuticals Inc. company’s key revenue driversInvest confidently with market-leading analysis - Jammu Links News
Does Madrigal Pharmaceuticals Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News
What is the dividend policy of Madrigal Pharmaceuticals Inc. stockBuild wealth faster with expert stock selection - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a good long term investmentUnlock your portfolio’s hidden potential - Jammu Links News
What makes Madrigal Pharmaceuticals Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News
The week in pharma: action, reaction and insight – week to August 1 - The Pharma Letter
Published on: 2025-08-03 13:27:37 - Jammu Links News
When is Madrigal Pharmaceuticals Inc. stock expected to show significant growthDiscover hidden gems in the stock market - Jammu Links News
What are analysts’ price targets for Madrigal Pharmaceuticals Inc. in the next 12 monthsExceptional risk-adjusted gains - Jammu Links News
Should I hold or sell Madrigal Pharmaceuticals Inc. stock in 2025Access daily stock market expert updates - Jammu Links News
What are the technical indicators suggesting about Madrigal Pharmaceuticals Inc.Market Forecast Opportunities Backed By Experts - Jammu Links News
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term (MDGL) - Seeking Alpha
Madrigal in-pact with CSPC Pharma for obesity drug license - MSN
Analyzing recovery setups for Madrigal Pharmaceuticals Inc. investorsSwing Trade Entry With Volume Triggers Released - metal.it
Non-Alcoholic Steatohepatitis Market Set to Grow - openPR.com
Madrigal Pharmaceuticals Enters into Exclusive Global - GlobeNewswire
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal Pharmaceuticals' Strategic Licensing Deal: A Pivotal Move in the NASH Therapeutics Arms Race - AInvest
Madrigal inks license deal with CSPC Pharma - The Pharma Letter
Madrigal in-pact with CSPC Pharma for GLP-1 candidate license - Seeking Alpha
Madrigal obtains rights to CSPC Pharmaceutical’s SYH-2086 - BioWorld MedTech
Madrigal Pharmaceuticals Signs Global License Agreement - TipRanks
Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra - Investing.com Nigeria
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Enters Exclusive License Agreement with CSPC for SYH2086 to Enhance MASH Treatment Pipeline - Quiver Quantitative
Madrigal secures global license for oral GLP-1 drug to combine with Rezdiffra By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals Inc (MDGL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):